Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke

Ki vehet részt

• 1. Age 18-80 years, regardless of gender
• 2. Clinically diagnosed with acute ischemic stroke and meets the criteria for tenecteplase intravenous thrombolysis
• 3. Onset of the current stroke within 4.5 hours
• 4. Clinical diagnosis of minor ischemic stroke with a NIHSS score of 2-5, accompanied by persistent unilateral limb weakness or speech symptoms, defined as a score ≥1 on either the language item or any one limb item of the NIHSS
• 5. Pre-stroke mRS score ≤1
• 6. The subject or their legal representative is able and willing to sign the informed consent form

Ki nem vehet részt

• 2. Patients who have received or plan to undergo mechanical thrombectomy
• 8. Patients treated with drugs containing butylphthalide after stroke onset
• 12. Subjects with concurrent malignant tumors or severe systemic diseases, with an expected survival of <90 days
• 13. Patients who have participated in other clinical interventional studies within 30 days prior to randomization, or who are currently participating in other clinical interventional studies
• 1. History of intracranial hemorrhage
• 3. History of major head trauma or stroke within the past 3 months
• 6. Patients with bradycardia (heart rate <60 beats/min) or sick sinus syndrome
• 7. History of drug/food allergy or known allergy to the components of the study drugs
• 9. History of congenital/acquired hemorrhagic diseases, coagulation factor deficiency, or thrombocytopenic diseases
• 11. Subjects with severe mental disorders or dementia who cannot cooperate with informed consent and follow-up
• 4. Known severe liver/kidney dysfunction or patients receiving dialysis (severe liver dysfunction: ALT/AST >3 times the upper limit of normal; severe kidney dysfunction: serum creatinine >3.0 mg/dl [265.2 μmol/L] or GFR <30 ml/min/1.73 m²)
• 5. Systolic blood pressure <90 mmHg or >220 mmHg
• 10. Pregnant or lactating subjects or subjects planning to become pregnant within 90 days
• 14. Patients who are unable to complete follow-up visits as scheduled
• 15. Any other reasons that, in the investigator's opinion, render the patient unsuitable for participation in the study